Please login to the form below

Not currently logged in
Email:
Password:

Alzheon

This page shows the latest Alzheon news and features for those working in and with pharma, biotech and healthcare.

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Earlier this week another drug in that category, Alzheon’s tramiprosate, also reported some encouraging data in a mid-stage trial, although that involved a subgroup of patients with a genetic

Latest news

  • Alzheon says data backs potential of Alzheimer's candidate Alzheon says data backs potential of Alzheimer's candidate

    Four years ago, US biotech Alzheon took a gamble on Alzheimer's candidate tramiprosate, thinking it saw potential in the drug despite a failed phase III trial. ... Like dozens of other shelved amyloid-targeting agents, it would have been all-but

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    Former GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon. ... Alzheon's founder, president and chief executive officer Martin Tolar said:

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics